secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001193125-23-209874
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q2 net loss $21.2M; Phase 3 melanoma trial reaches 225-patient milestone; $75M private placement closed
--------------------------------------------------------------------------------

- Net loss of $21.2M (vs $18.5M Q2 2022); R&D spend $16.5M on Phase 3 trial execution.
- Cash and equivalents $110.1M; expected to fund operations into Q4 2025.
- Phase 3 IOB-013/KN-D18 enrolled 225 patients; target raised to 380, full enrollment by end 2023.
- Interim ORR analysis one year post 225 randomized may support US accelerated BLA submission.
- Appointed Heidi Hunter to Board; Priyanka Belawat resigned; closed $75M private placement (37M shares+warrants).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/d524431d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer